4244-81-9Relevant academic research and scientific papers
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity
Gromek, Samantha M.,deMayo, James A.,Maxwell, Andrew T.,West, Ashley M.,Pavlik, Christopher M.,Zhao, Ziyan,Li, Jin,Wiemer, Andrew J.,Zweifach, Adam,Balunas, Marcy J.
supporting information, p. 5183 - 5196 (2016/10/24)
Santacruzamate A (SCA) is a natural product isolated from a Panamanian marine cyanobacterium, previously reported to have potent and selective histone deacetylase (HDAC) activity. To optimize the enzymatic and cellular activity, 40 SCA analogues were synthesized in a systematic exploration of the zinc-binding group (ZBG), cap terminus, and linker region. Two cap group analogues inhibited proliferation of MCF-7 breast cancer cells, with analogous increased degranulation of cytotoxic T cells (CTLs), while one cap group analogue reduced CTL degranulation, indicative of suppression of the immune response. Additional testing of these analogues resulted in reevaluation of the previously reported SCA mechanism of action. These analogues and the resulting structure–activity relationships will be of interest for future studies on cell proliferation and immune modulation.
Synthesis and biological evaluation of santacruzamate A and analogs as potential anticancer agents
Liu, Qi,Lu, Wenhua,Ma, Mingzhe,Liao, Jianwei,Ganesan,Hu, Yumin,Wen, Shijun,Huang, Peng
, p. 1109 - 1112 (2015/02/05)
Santacruzamate A, a recently discovered natural product from a Panamanian marine cyanobacterium Symploca sp., features a similar structure to the clinically used histone deacetylase (HDAC) inhibitor vorinostat (SAHA). We have synthesized the natural product and a small set of analogues for SAR studies. To our surprise, the synthetic natural product santacruzamate A (1a) and the analogues did not show an obvious inhibition even at 2 μM in HDAC enzyme assays while the IC50 value was 0.12 nM in the original report. However, a novel compound, 5, containing a terminal thiourea motif was found to inhibit the growth of malignant cells at submicromolar concentrations. Moreover, 5 was not cytotoxic to normal human colonic epithelial cells CCD841, suggesting that its cytotoxicity was specific to cancer cells. Further investigation indicated that the compound induced apoptosis, affected cell cycle progression and increased ROS production. We believe its mechanism of action is unrelated to HDAC inhibition and the original activity reported for santacruzamate needs to be reevaluated.
SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE
-
Page/Page column 63, (2014/02/16)
The compositions and methods described herein relate generally to Santacruzamate A compositions and analogs, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.
Design, Synthesis, ADME Properties, and Pharmacological Activities of β-Alanyl-D-histidine (D-Carnosine) Prodrugs with Improved Bioavailability
Orioli, Marica,Vistoli, Giulio,Regazzoni, Luca,Pedretti, Alessandro,Lapolla, Annunziata,Rossoni, Giuseppe,Canevotti, Renato,Gamberoni, Luca,Previtali, Massimo,Carini, Marina,Aldini, Giancarlo
experimental part, p. 1269 - 1282 (2012/05/20)
β-Alanyl-D-histidine (D-CAR, the enantiomer of the natural dipeptide carnosine) is a selective and potent sequestering agent of reactive carbonyl species (RCS) that is stable against carnosinase, but is poorly absorbed in the gastrointestinal tract. Herein we report a drug discovery approach aimed at increasing the oral bioavailability of D-CAR. In our study we designed, synthesized, and evaluated a series of novel lipophilic D-CAR prodrugs. The considered prodrugs can be divided into two categories: 1)derivatives with both terminal groups modified, in which the carboxyl terminus is always esterified while the amino terminus is protected by an amidic (N-acetyl derivatives) or a carbamate (ethyloxy or benzyloxy derivatives) function; 2)derivatives with only one terminus modified, which can be alkyl esters as well as amidic or carbamate derivatives. The prodrugs were designed considering their expected lipophilicity and their hydrolysis predicted by docking simulations on the most important human carboxylesterase (hCES1). The stability and metabolic profile of the prodrugs were studied by incubating them with rat and human serum and liver fractions. The octyl ester of D-CAR (compound 13) was chosen as a candidate for further pharmacological studies due to its rapid hydrolysis to the bioactive metabolite invitro. Pharmacokinetic studies in rats confirmed the invitro data and demonstrated that the oral bioavailability of D-CAR is increased 2.6-fold if given as an octyl ester relative to D-CAR. Compound 13 was then found to dose-dependently (at daily doses of 3 and 30mgkg-1 equivalent of D-CAR) decrease the development of hypertension and dyslipidemia, to restore renal functions of Zucker fa/fa obese rats, and to inhibit the carbonylation process (AGEs and pentosidine) as well as oxidative stress (urinary 8-epi-prostaglandin F2α and nitrotyrosine). A plausible mechanism underlying the protective effects of 13 is RCS sequestration, as evidenced by the significant increase in the level of adduct between CAR and 4-hydroxy-trans-2-nonenal (HNE, the main RCS generated by lipid oxidation) in the urine of treated animals. The modest oral absorption of D-carnosine (D-CAR), a bioactive compound able to detoxify reactive carbonyl species, prompted us to design, synthesize, and evaluate new lipophilic D-CAR prodrugs. Among these, D-CAR with an octyl ester has greater oral bioavailability than D-CAR, as demonstrated by pharmacokinetic studies. The new compound reduces the development of hypertension and dyslipidemia, and restores renal function in Zucker fa/fa obese rats.
DIPEPTIDE COMPOUNDS CONTAINING D-HISTIDINE
-
Page/Page column 3, (2009/12/24)
D-Camosine lipophilic derivatives are disclosed, characterized by higher bioavailability than L-camosine and intended for the pulmonary distribution where they can exert detoxifying activity on the cytotoxic carbonyl compounds induced by cigarette smoke.
Butyl 2-(4-[1.1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain
Liberatore, Anne-Marie,Schulz, Jocelyne,Favre-Guilmard, Christine,Pommier, Jacques,Lannoy, Jacques,Pawlowski, Emilia,Barthelemy, Marie-Anne,Huchet, Marion,Auguet, Michel,Chabrier, Pierre-Etienne,Bigg, Dennis
, p. 1746 - 1749 (2008/02/07)
A series of 4-arylimidazole carbamates was synthesized and their binding affinities to the site-2 sodium (Na+) channel were determined. SAR studies led to the identification of compound 10, a potent Na+ channel blocker which was efficacious in pain models in vivo.
Flash vacuum pyrolysis of stabilised phosphorus ylides. Part 17. Preparation of aliphatic amino acid derived γ-alkoxycarbonyl-amino-β-oxo ylides and pyrolysis to give α,β-acetylenic γ-amino acid and GABA analogues
Aitken, R. Alan,Karodia, Nazira,Massil, Tracy,Young, Robert J.
, p. 533 - 541 (2007/10/03)
A series of eleven α-aminoacyl stabilised phosphorus ylides 9-19 have been prepared by condensation of N-alkoxycarbonyl protected amino acids with Ph3P = CHCO2Et using a carbodiimide peptide coupling reagent. Upon flash vacuum pyrolysis at 600 °C, these undergo extrusion of Ph3PO to give the corresponding α,β-acetylenic γ-amino esters 21-29, 33 and 34 in moderate yield. In two cases the terminal alkynes 30 and 31 are also formed. The β-aminoacyl ylide 20 from β-alanine similarly gives the α,β-acetylenic δ-amino ester 35 upon pyrolysis. Regioselective addition of HBr to the triple bond of one acetylenic ester 25 was observed giving a mixture of E and Z α-bromoacrylates 36. Hydrogenation of the N-Cbz acetylenic esters 21-23 and 33 results in N-deprotection and hydrogenation of the triple bond to afford the chiral GABA analogues 37-40 in 70 ->95% ee as determined by 19F NMR of their Mosher amides. Fully assigned 13C NMR spectra of all the ylides and acetylenic ester derivatives are presented.
